Over the last quarter, the amount of capital focused on the Canadian cannabis sector has increased significantly. While we remain very focused on Canadian licensed medical marijuana producers, we have also focused on companies that are levered to the legal cannabis industry but are not involved in the cultivation or sale of marijuana.

We remain bullish on Canadian licensed medical marijuana producers, but believe there are several attractive long-term opportunities capitalizing on other facets of the industry.

One company that falls under this category is Isodiol International Inc. (ISOL.CN) (ISOLF) a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products. The company continues to increase its global footprint and execute on a diverse array of initiatives.

Continues to Increase Market Share and Enter New Markets

Isodiol continues to expand its reach and has successfully entered new markets. We are favorable on these developments and expect the company to enter several new markets over the next year.

One of the exciting developments in this area for Isodiol took place earlier this month when they announced that they were entering Chile. Chile were the first South American country to legalize the sale of cannabis-based medicines in pharmacies.

In 2015, Chile legalized the use of medicinal marijuana and is among several Latin American countries gradually loosening laws prohibiting the cultivation, distribution, and consumption of cannabis. Isodiol is one of the first companies to register a cannabidiol (CBD) product with the Chilean Health Department.

The Newly Minted Phytoceutical Division Bears Fruits

Today, Isodiol announced that its Phytoceutical division announced the launch of the market’s first non-cannabis, highly bioactive cannabinoid, CBD, derived from the Hops plant. This is a breakthrough for the company and we are bullish on this announcement as Isodiol expects to launch the first product in the next month.

We believe that the development of the technology to extract cannabinoids from a plant other than a cannabis, is a remarkable achievement and we will keep an eye on how Isodiol continues to execute from here.

Sourcing natural, highly bioactive cannabinoids to supplement the endocannabinoid system in the human body is the key to developing targeted health care remedies. Hops derived cannabinoid products have shown a very favorable response and promising results in independent clinical studies for various diseases. The company will continue to collaborate with universities and alternative health facilities in the US and overseas to validate the science.

This breakthrough will help Isodiol increase distribution of its portfolio of CBD products and this is something to watch. Going forward, the company will continue to collaborate with universities and alternative health facilities in the U.S. and overseas to validate the science.

Isodiol: A Long-Term Opportunity

We are favorable on Isodiol International and continue to monitor the shares closely. Isodiol has come off its recent highs and we believe that the pullback has created a great opportunity for new investors.

Isodiol is led by a management team that continues to execute and enter new markets. The company has also been putting up strong revenue numbers and we expect this trend to not only continue but ramp higher.

Although the shares have been trending lower, Isodiol has come off its monthly lows after the shares found support at $0.26 and we remain bullish on the long-term opportunity. We recommend keeping an eye on Isodiol as the company continues to execute and will monitor how the market responds to today’s breakthrough.